Compare Cassava Sciences Inc (FLNA) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Illinois Tool Works Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Illinois Tool Works Inc. trades at $279.1 (market cap $78.08B). The key difference: Illinois Tool Works Inc. is far larger — about 1469.3× Cassava Sciences Inc's market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ITW | |
|---|---|---|
Market Cap | $53.14M | $78.08B |
Sector | Health | Industrials |
52-Week High | $4.64 | $299.60 |
52-Week Low | $1.09 | $241.07 |
Enterprise Value | -$33.43M | $86.41B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
Illinois Tool Works (ITW) trades at $272.28, up 0.29% on the day, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.66 surpassing expectations. ITW maintains strong profitability, with a net income margin of 19.32% and ROE of 96.88%, supported by solid cash flow from operations of $3.13B in 2025. Recent news highlights segment strength and a declared dividend of $1.61 per share for Q2 2026.
ITW presents a mixed outlook with robust fundamentals and technical strength offset by valuation concerns and modest growth. The consensus price target of $288.25 implies potential upside, but high P/E and P/B ratios suggest limited margin of safety. Risks include construction sector weakness and currency headwinds. Earnings on July 28, 2026, will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
